1. Home
  2. HOV vs PRME Comparison

HOV vs PRME Comparison

Compare HOV & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hovnanian Enterprises Inc.

HOV

Hovnanian Enterprises Inc.

HOLD

Current Price

$133.70

Market Cap

645.8M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.81

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOV
PRME
Founded
1959
2019
Country
United States
United States
Employees
1891
N/A
Industry
Homebuilding
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.8M
536.4M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
HOV
PRME
Price
$133.70
$3.81
Analyst Decision
Sell
Buy
Analyst Count
2
6
Target Price
$97.00
$7.56
AVG Volume (30 Days)
114.6K
3.4M
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
N/A
$7.06
Revenue Next Year
$5.96
$47.01
P/E Ratio
$17.50
N/A
Revenue Growth
N/A
55.28
52 Week Low
$91.52
$2.67
52 Week High
$162.06
$6.94

Technical Indicators

Market Signals
Indicator
HOV
PRME
Relative Strength Index (RSI) 58.11 65.67
Support Level $97.80 $3.16
Resistance Level N/A $4.04
Average True Range (ATR) 8.22 0.29
MACD 0.71 0.10
Stochastic Oscillator 57.05 71.15

Price Performance

Historical Comparison
HOV
PRME

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: